Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- Microsatellite StableMismatch Repair ProficientStage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Refractory Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT04119830
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer
Not Applicable
Terminated
- Conditions
- Head and Neck Lymph NodeHead and Neck Squamous Cell CarcinomaRadiation Therapy RecipientHead and Neck CarcinomaLaryngeal Neoplasm
- Interventions
- Procedure: Photoacoustic ImagingProcedure: Transcutaneous Acupoint Electrical Stimulation
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT04110249
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Phase 2
Active, not recruiting
- Conditions
- Advanced Colorectal CarcinomaMetastatic Colon AdenocarcinomaRecurrent Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Unresectable Colon AdenocarcinomaRecurrent Rectal Adenocarcinoma
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT04109924
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2
Completed
- Conditions
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT04097028
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈStephenson Oklahoma Cancer Center at the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Phase 2
Terminated
- Conditions
- HLA-A2 Positive Cells PresentRefractory Melanoma
- Interventions
- Biological: Alpha-type-1 Polarized Dendritic CellsDrug: PD-1 Ligand InhibitorDrug: PD1 Inhibitor
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT04093323
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Phase 1
Completed
- Conditions
- HER2/Neu NegativeProgesterone Receptor NegativePrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Triple-Negative Breast CarcinomaAnatomic Stage IIA Breast Cancer AJCC v8
- Interventions
- Biological: Recombinant Interferon Alfa-2b
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT04081389
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Stage IIIA Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Resected MassStage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Lung Non-Small Cell CarcinomaPositive Surgical Margin
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04073745
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Malignant Neoplasm
- Interventions
- Radiation: Palliative Radiation TherapyOther: Quality-of-Life AssessmentRadiation: Stereotactic Body Radiation TherapyOther: Questionnaire Administration
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1500
- Registration Number
- NCT04068649
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈThe Cancer Institute at St. Francis Hospital, East Hills, New York, United States
πΊπΈGood Samaritan Hospital, West Islip, New York, United States
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Phase 2
Recruiting
- Conditions
- Stage IA2 Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage I Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8
- Interventions
- Other: Best PracticeProcedure: Laparoscopic SurgeryOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationProcedure: Video-Assisted Thoracic SurgeryDevice: Respiratory Muscle Training Device
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 220
- Registration Number
- NCT04067830
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Effects of Filter Ventilation on Sensory Response, Smoking Topography, and Inhalation in Current Every Day Cigarette Smokers
Completed
- Conditions
- Current Every Day SmokerCigarette Smoker
- Interventions
- Device: Medical DeviceOther: Questionnaire AdministrationBehavioral: Tobacco Smoking
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT04060446
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States